跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 164 条关于
“FGF4”
全部
164
临床试验
120
药物
28
机构
0
资讯
16
3个月前
Rogaratinib Achieves 41.7% Response Rate in SDH-Deficient GIST, Demonstrating Breakthrough Efficacy for Previously Untreatable Tumor Subtype
去年
Tyra Biosciences' FGFR3 Inhibitor TYRA-300 Shows Promise in Urothelial Cancer
去年
Rogaratinib Plus Atezolizumab Shows Promise in FGFR mRNA-Overexpressing Urothelial Cancer
11年前
Tyra Biosciences Advances FGFR Inhibitor Pipeline with Multiple Clinical Trials
去年
TAR-210 Shows Promise in FGFR-Altered Non-Muscle Invasive Bladder Cancer
去年
Rogaratinib Plus Atezolizumab Shows Promise in Cisplatin-Ineligible Urothelial Cancer
去年
Abbisko's FGFR4 Inhibitor Irpagratinib Receives China's Breakthrough Therapy Designation for Hepatocellular Carcinoma
去年
TAR-210 Shows Promise in FGFR-Altered Non-Muscle Invasive Bladder Cancer
2年前
Tyra Biosciences Reports Increased R&D Investment Fueled by FGFR-Targeted Therapies
去年
Eisai Seeks Japanese Approval for Novel FGFR Inhibitor Tasurgratinib in Biliary Tract Cancer
第 1 页,共 2 页
上一页
下一页